Pfizer Inc. has recently seen how sales of its biggest-selling drug, anti-cholesterol medication Lipitor, started falling when it had to compete with cheaper generic versions. The pharmaceutical giant was determined not to let that happen to its number-two cash cow, anti-pain and seizure drug Lyrica.
On July 18, Pfizer turned aside a challenge from eight generic drug companies seeking to invalidate three patents relating to Lyrica. The patents, which were held by Northwestern University, had been granted to Pfizer under an exclusive license. Led by Teva Pharmaceutical Industries Ltd., the world’s largest generic-drug manufacturer, the challengers had hoped to make cheaper versions of the drug immediately, and had filed abbreviated new drug applications with the Federal Drug Administration. White & Case and Morris, Nichols, Arsht & Tunnell represented Pfizer, while McCarter & English represented Northwestern. Teva, meanwhile, was represented by Kenyon & Kenyon.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
